Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think Vanilla shares the same frustrations as many of us. There are so so many .00x and .000x plays that have ran to .5 range for massive returns while this remains stagnant. There’s quite a few .000x plays that are multi dollars since December even. Even if you bought Dogecoin, some BS meme coin you would be sitting on 1,300% gains. And that’s a b/s crypto with no real value.
Completely unexpected open. But the entire OTC appears to be in the red. All my other holdings seemed to take a hit today.
As long as the stock maintains strong momentum like it did yesterday, Clay won’t have an entry point for shorting this. Which after the monster 2.23b shares traded yesterday, I doubt we will see less than 1.5b shares traded today as the remaining float gets absorbed by new traders. This thing has had to hit many, many volume and price action scanners of people looking to jump the next .00 train into copper/silver territory
Good morning Berkshire! We ready for another multi-bagger run today?? Another 2b volume day and there will be 0 float to go around!
400% run yesterday, we only need 42% to hit our first penny. With how strong we closed, we will easily blow past that with almost half the O/S traded yesterday! Last time I seen volume this high on a 5b o/s stock, Nokia ran from 5$ to 9$ by lunch the next day. Would love to see what this will do with a second day of 2b volume of ask slapping. Blue skies?
I can see .015 easily. The volume and the ask slapping was unreal. This hasn’t hit stocktwits or yahoo’s radar yet. I was going to be glad to see a .0055 close for a bullish signal, but closing at .007? I think that exceeded all of our expectations!
We just traded 45% of the o/s. That’s what I call MASSIVE VOLUME! And the Yoo-hoo, Stonk-twits, and Deddit crowd hasn’t woken up to this.
1.7b shares traded. Float is disappearing fast.
Lunch time profit taking almost over. Power hour here we come.
200-300% runs always have a healthy pullback. This could easily see 1000% on the week imo. People are just selling half at the moment and playing with free money. I’m sure they will regret it later in the week when they see what they just left on the table.
Nice dip. Once profit taking is over, we are headed for copper then silver. They are about to miss out on the next ENZC
Was the conference call just for big time investors like GEM and Princeton? I’m a little bewildered as why we were just left in the dark with no explanation.
A video interview said results are expected this week on the IV trial
January 28th was the primary endpoint date from final enrollment. I’m sure the DMC still has to take time to review all patient data now that it has been unblinded to them. Then of course all the paperwork, reports, red tape etc. we could easily be another week out from any serious PR. Then again OWS/BARDA might want first crack at the data before us common shareholders ever get to see it. Just a thought. There are more important cogs in this machine other than is small guys. Let’s just hope the data is soon and it is good.
Interesting after hours action
Not only that, seems like the execs were quick to exercise their stock options last week.
OWS really showed us one thing. The previous administration was heavy on self interest and cronyism. I was never big on the push to see tax returns. But I would love to just have a peak and see how many shares of Moderna, Regeneron, Pfizer and lily are in his personal portfolio. OWS really just became another stunt to funnel money into major corporations. I hope that the new admin really stays true to its claims. It was a relief to see Fauci yesterday on the press briefing.
Maybe, just maybe we are going to finally head in the right direction.
$BUSXF
3 trade channels have developed based on yesterdays action. With this being in the EV sector now and growing public awareness, I have a hard time believing that we will follow in the horizontal channel for much longer.
Only 3 factors that I have found could potentially explain yesterdays horizontal trading.
1. PR firm is paid in shares
2. Execs are paid in shares
3. Profit taking from being up 90% since the new channel began.
For those that bought shares yesterday in the first hour of trading, such as myself, I am still seeing a bullish pattern based on yesterdays action with plenty of upside potential near future to get us back into the previous trading zones. High probability of a gap up near term putting us into the +3$ range
News
Leading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular Surgery
LBS expects to initiate a pivotal trial in 2021
https://www.globenewswire.com/fr/news-release/2021/01/13/2157904/0/en/Leading-BioSciences-Announces-FDA-Fast-Track-Designation-Granted-to-LB1148-for-the-Treatment-of-Postoperative-Gastrointestinal-Dysfunction-Associated-with-Pediatric-Cardiovascular-.html
3 janv. 2021 08h30 HE | Source : Leading BioSciences
CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca Biopharma, Inc. (Nasdaq: SNCA) to form Palisade Bio, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to LB1148 for the treatment of postoperative gastrointestinal (GI) dysfunction associated with pediatric heart surgery.
“Even with high success rates of neonatal heart surgery, longer-term outcomes in pediatric patients are, to a great extent, dependent upon the speed of postoperative recovery of GI function,” said Dr. Michael Dawson, Chief Medical Officer of Leading BioSciences. “By awarding Fast Track Designation to LB1148 for the treatment of pediatric patients undergoing open-heart surgery, the FDA has recognized LB1148’s potential to accelerate return of bowel function and reduce the risk of serious and life-threatening complications associated with corrective surgeries for these patients, a condition for which no therapy currently exists. This is an important acknowledgement and will improve the frequency of our dialogue with the agency as we initiate our pivotal study.”
The FDA Fast Track program is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. With Fast Track designation LBS is eligible for greater access to the FDA for the purpose of expediting clinical development and creates eligibility for accelerated approval and priority review of LB1148.
Previously, LBS announced positive topline data from a Phase 2, randomized, double-blind, placebo-controlled, study that enrolled 120 adult open-heart surgery patients. This trial evaluated return of bowel function in adult patients undergoing open-heart surgery with cardiopulmonary bypass. The LB1148-treated group demonstrated a statistically significant improvement of approximately 30% in the median time to return of normal bowel function as compared to the placebo treatment group (p<0.001). Generally, treatment with LB1148 was well tolerated. Adverse events were similar between the treatment groups and not unexpected for the subject population.
In addition to adult open-heart surgery patients, there is a tremendous unmet need for improving GI recovery in neonates undergoing heart surgery. By accelerating a return of GI function and full feeding following surgery, LB1148 may minimize the risk of developmental delays and other serious complications. LBS is planning to initiate a randomized, double-blind, placebo-controlled, multicenter Phase 3 clinical trial of LB1148 in neonatal patients undergoing elective on-pump open-heart surgery to correct congenital heart defects in 2021.
Tom Hallam, Ph.D., Chief Executive Officer of Leading BioSciences added, “There are currently no therapies available to treat GI dysfunction in pediatric patients undergoing open-heart surgery. We are thrilled that the FDA granted Fast Track designation to LB1148 for this indication. We believe this recognizes LB1148’s potential to demonstrate meaningful improvements in bowel recovery that are commensurate with the improvements demonstrated in our Phase 2 study in adult heart surgery patients.”
About LB1148
LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays.
About Leading BioSciences, Inc.
Leading BioSciences is developing novel therapeutics designed to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. LBS’ initial focus is combatting the interruption of GI function (ileus) following major surgery in order to reduce recovery times and shorten the duration of patient hospital stays. Additionally, LBS believes that its investigational therapies have the potential to prevent the formation of postoperative adhesions (reducing hospital re-admissions and additional surgeries), as well as to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal mucosal barrier. As of December 2020, Leading BioSciences has entered into a definitive agreement with Seneca Biopharma, Inc. under which a wholly owned subsidiary of Seneca will merge with Leading BioSciences in an all-stock transaction. The combined company is expected to operate under the name Palisade Bio, Inc. (Nasdaq: PALI), upon completion of the merger.
No Offer or Solicitation:
This communication will not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Important Additional Information Will be Filed with the SEC
In connection with the proposed transactions between LBS and Seneca, Seneca filed a registration statement on Form S-4 that contained a proxy statement and prospectus with the Securities Exchange Commission (“SEC”) on December 23, 2020, but the registration statement has not yet become effective. This communication is not a substitute for the registration statement or the proxy statement or any other documents that Seneca may file with the SEC or send to its stockholders in connection with the proposed transactions. BEFORE MAKING ANY VOTING DECISION, SENECA URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SENECA, THE PROPOSED TRANSACTION AND RELATED MATTERS.
You may obtain free copies of the registration statement, proxy statement and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the website maintained by the SEC at www.sec.gov. The registration statement is available free of charge on Seneca’s website at www.senecabio.com, by contacting Seneca’s Investor Relations by phone at (301) 366-4960, or by electronic mail at investor@senecabio.com. Investors and stockholders are urged to read the registration statement, proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.
Participants in the Solicitation
Seneca and LBS, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Seneca’s directors and executive officers is included in Seneca’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 27, 2020, and the proxy statement for Seneca’s 2020 annual meeting of stockholders, filed with the SEC on June 24, 2020. Additional information regarding these persons and their interests in the transaction is included in the proxy statement relating to the transaction. These documents can be obtained free of charge from the sources indicated above.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to the timing and results of clinical trials, and other statements that are not historical facts. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “will,” and similar expressions and their variants. These forward-looking statements are based upon LBS’s current expectations. Forward-looking statements involve risks and uncertainties, and actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Except as required by law, LBS expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in LBS’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Leading BioSciences Media Relations Contact:
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com
Leading BioSciences Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Corporate Contact:
Justin Stege, Ph.D.
justin.stege@leadingbiosciences.com
Revenue anticipated Q1 2020
Covid detection and possible covid detecting masks!
Cannabis Polymer tech
This looks like it has potential to be a runner
New corporate presentation slideshow just posted.
https://ir.redhillbio.com/static-files/f465e5e9-5f4d-4f71-9584-b7958715e8d5
Curious. All Russian sites are changed from (active, recruiting) to (active, not recruiting) must have hit target enrollment for Russia?
Did we ever hear anything back from that firm RT hired back in what, September? To set up and conduct Euro trials. Are they still around?
Excellent news!
Makes me wonder if I’ve been charged in the background? I play the swings to increase my position when ever we have worth while pullbacks.
I’ve never been charged a foreign fee on TD. Only the standard 6.95 otc fee.
EOY tax sale for most.
I sold my shares at 9.60 on Monday anticipating a pullback. Kept my April calls. Looking at a nice 8-8.50 re-entry if we don’t get news premarket tomorrow
I seen something like this going to happen so I took my chips off the table prior to today. Get back in at a beautiful discount with even more shares than before and brought my average way back down. My only regret is that it didn’t tank to .20
EOY tax sales are coming. Will be a good week to get discount shares.
MM’s just ran outa shares? BRRRRRR MOON
Do you have a link? I’m thinking I need to add more calls to my options list.
Nice! I don’t have the spare capital or the risk tolerance to be that deeply invested. But I think we all have a real opportunity to make great returns in the near future if all goes well!
My current position-
500 shares and 25 calls for 20$ with an April 21st expiration.
If the news is good, we could see about a 28-30$ PPS. With a potential FOMO overshoot to $37
to $44.
Of course if the news is not great I eat crow at 6-7$ a share.
I’ve moved some chips back into this one after taking a few month hiatus. Probably more exposed than I want to be. But this has traded sideways for a better part of 6 months. The way the market has been reacting lately it only takes a small spark to hit a 300% gainer over night with these sideways traders.
Results anticipated in 2021. So no immediate readout.
Over 200 enrolled in the double blind trial. Oh look. The goalposts. They moved again.
What happened to that all star team relief hired to run the Euro trials 3 months back? Was that just more BS fluff PR?